Dasatinib is a multi-target protein tyrosine kinase inhibitor.Due to its potent inhibition of Src,Abl,the platelet-derived growth factor receptor (PDGFR) family kinases,and other oncogenic kinases,it has been investigated as a targeted therapy for a broad spectrum of cancer types.However,its efficacy has not been significantly extended beyond leukemia.The mechanism of resistance to dasatinib in a wide array of cancers is not clear.In the present study,we investigated the effect of dasatinib on hepatocellular carcinoma cell growth and explored the underlying mechanisms.Our results showed that dasatinib potently inhibited the proliferation of SNU-449 cells,but not that of other cell lines,such as SK-Hep-1,even though it inhibited the phosphorylation of Src on both negative and positive regulation sites in all these cells.Dasatinib activated the phosphoinositide-dependent protein kinase1 (PDK1)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR)signaling pathway in SK-Hep-1 cells,but not in SNU-449 cells.Blocking the Akt/mTOR signaling pathway strongly promoted the efficacy of dasatinib in SK-Hep-1 cells.In SNU-449 cells,dasatinib promoted apoptosis and the cleavage of caspase-3 and caspase-7,induced cell cycle arrest in the G1 phase,and inhibited the expression of Cyclin-dependent kinase (CDK4)/6/CyclinD1 complex.These findings demonstrate that dasatinib exerts its anti-proliferative effect on hepatocellular cell prolif-eration by blocking the Src family kinases;however,it causes Akt activation,which compromises dasatinib as an anti-cancer drug.